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Zhong et al. reported the results of the ADJUVANT/
CTONG1104 study (1), a randomized open-label phase 
III trial enrolling 483 Chinese patients with completely 
resected (R0) stage II–IIIA (N1-N2) non-small cell lung 
cancer (NSCLC) and epidermal growth factor receptor 
(EGFR)-mutant (defined as exon 19 deletion or exon 
21 Leu858Arg) to receive 4 cycles of standard adjuvant 
Cisplatin and Vinorelbine or 24 months of the EGFR-
tyrosine kinase inhibitor (TKI), gefitinib. The primary end-
point was disease free survival (DFS). Secondary endpoints 
included overall survival (OS), 3-year DFS, 5-year DFS, 
and 5-year OS, safety, tolerability and quality of life. From 
the initial screening of 483 patients, 222 (45.9%) were 
eligible and randomly assigned to standard chemotherapy 
or experimental arm. At a median follow-up of 36.5 months, 
the median DFS was significantly longer in the gefitinib 
arm than in chemotherapy arm (28.7 vs. 18.8 months; HR 
0.6; 95% CI, 0.42–0.87; P=0.0054). Among secondary end-
points, OS data were not mature and, thus, not reported; 
3-year DFS favored the gefitinib group and a reduced 
toxicity with improvement in quality of life was observed 
with adjuvant gefitinib compared to chemotherapy. 
Particularly, the most commonly reported grade 3 or 
worse adverse events were raised alanine and aspartate 
aminotransferase in the gefitinib group, neutropenia, 
leucopenia and vomiting in the chemotherapy group, which 
were absent in gefitinib arm. Serious adverse events were 
reported in 7 (7%) patients who received gefitinib and 20 
(23%) patients who received vinorelbine plus cisplatin. 
The authors concluded that adjuvant gefitinib could be 
considered as a treatment option for selected patients with 
EGFR-mutated NSCLC (1).
To date, 20–25% of patients affected by NSCLC are 
candidates to radical surgery, but a substantial percentage 
of them subsequently relapse and die of their disease. 
Several studies and meta-analyses have confirmed the 
role of cisplatin-based adjuvant chemotherapy as the 
standard of care for patients with resected stage II–IIIA 
NSCLC, irrespectively of any tumour mutational status 
(2,3). Particularly, two trials (ANITA and North American 
Intergroup Trial) highlighted the role of vinorelbine in 
addiction to cisplatin as adjuvant treatment for stage IB, 
II and IIIA NSCLC (4,5). Unfortunately, the addition of 
post-surgery chemotherapy in this population resulted into 
an absolute 4–5% improvement in OS at 5 years (6,7), this 
resulting in still disappointing 5-year survival rates for stage 
II–IIIA NSCLC patients. Therefore, the improvement of 
outcome of adjuvant treatment represents a challenge in the 
management of radically resected NSCLC and, at present, 
no targeted therapy showed to improve survival when added 
to standard adjuvant chemotherapy in a randomized phase 
III trial. For example, the addition of the antiangiogenic 
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agent, bevacizumab to adjuvant chemotherapy did not 
improve the outcome of patients with surgically resected 
early-stage NSCLC in the E1505 trial (5).
The first druggable abnormalities discovered in lung 
cancer are EGFR tyrosine kinase mutations that occur in 
approximately 10% of advanced NSCLC Western patients 
and in 30% of Asiatic patients. In the era of precision 
medicine, EGFR tyrosine kinase inhibitors (i.e., gefitinib, 
erlotinib, afatinib, icotinib, dacomitinib and, recently, 
osimertinib) have become the standard first-line treatment 
for NSCLC patients harbouring those specific mutations 
(8-12). Despite this, evidences supporting EGFR-TKIs as 
adjuvant treatment of EGFR-mutant early stage NSCLC 
are still scant and controversial. Recently, two retrospective 
analyses (13,14) and two prospective trials (15,16) showed 
promising results in improving DFS in EGFR-mutant stage 
I–III NSCLC patients who received adjuvant EGFR TKIs 
compared to who did not, and, collectively, this suggests a 
potential OS benefit for those patients (Table 1).
The ADJUVANT trial is the first head-to-head trial 
showing a superior DFS of targeted therapy vs. an adjuvant 
standard chemotherapy in a selected population of patients 
with radically resected EGFR-mutant NSCLCs with a high 
risk of recurrence (only N1 and N2 stage disease excluding 
stage IB). While this represents a pivotal result for NSCLC 
research field, it is important to note that this trial presents 
some limitations. First, as underlined by the authors, the OS 
data are still not available and, in the intention to treat (ITT) 
population, the Kaplan-Meier curves for DFS separated 
around 12 months and then came together to about 
36 months, suggesting that gefitinib maintained its clinical 
benefit for more than 10 months after stopping treatment 
at 24 months. Similar Kaplan-Meier curves were previously 
reported in a study of erlotinib versus placebo for NSCLC 
(RADIANT study) (15) and these authors concluded that 
EGFR-TKIs might not be curative as adjuvant treatment 
for patients with resected NSCLC, but rather provide 
clinical benefit for most patients delaying disease recurrence 
by roughly 10 months compared to chemotherapy. 
Although these data suggest that the benefit in favor of 
targeted therapy is clinically significant in patients properly 
selected based on the presence of an EGFR mutation, 
and that an EGFR-TKI may replace standard adjuvant 
chemotherapy, it is important to underline that lack of 
OS data is a major concern in the perspective to change 
current clinical practice in this specific setting. In fact, the 
aim of an adjuvant treatment is to eradicate the microscopic 
residual disease leading to the improvement in OS rather 
than DFS. The evidence that an EGFR-TKI could delay 
disease recurrence in high-risk NSCLC patients compared 
to standard chemotherapy is clinically relevant, but not 
sufficient to allow its wide use as adjuvant agent. Indeed, it 
is still unclear whether patients who do not receive up-front 
adjuvant targeted therapy may obtain an equal benefit by 
receiving it at disease recurrence. In addition, the median 
follow-up of 36.5 months seems not adequate enough 
considering the observed OS of 65.7 months in the ANITA 
trial and 85.8 months for control arm in the E1505 trial 
(4,5). For this reason, a longer follow-up with more mature 
data is awaited for definitive conclusions. In this setting, 
the ongoing ALCHEMIST study (NCT02201992), that 
is investigating adjuvant EGFR and ALK tyrosine kinase 
inhibitors in EGFR-mutant and ALK-positive NSCLC with 
a primary endpoint of OS may add important information.
Patients with IB NSCLC were not enrolled in the 
ADJUVANT trial. Stage I NSCLC is diagnosed in 
approximately 16% of all lung cancer cases (18) and the use 
of adjuvant chemotherapy showed improvement of OS for 
patients with tumors larger than 4 cm. Consequently, there 
is a strong rationale to investigate adjuvant EGFR TKIs 
also in IB EGFR-mutated NSCLC. In addition, another 
point to consider is that ADJUVANT trial recruited only 
Chinese patients, even though it is well known that the 
frequency of EGFR mutations is approximately 10% in 
Caucasian patients and up to 50% in Asian patients (19). 
This discrepancy may open some doubts about the 
reproducibility of data from ADJUVANT trial in a non-
Asian NSCLC setting and, thus, will require additional 
investigations in this subgroup of patients. On the other 
hand, a confirmatory trial in Western population is likely to 
meet a more difficult enrolment of patients due to the lower 
percentage of EGFR-mutant NSCLCs. Finally, the low 
percentage of dose reductions (11%), discontinuation for 
drug-related toxic effects (3%) and adverse events of grade 3 
or higher (12%) in the gefitinib arm of ADJUVANT trial 
may suggest the possibility of further studies with a longer 
duration of the EGFR-TKIs. However, it should be pointed 
out that most of available data on the activity of different 
EGFR-TKIs given in the adjuvant setting concomitantly 
or after standard chemotherapy derive from studies with a 
treatment duration of 24 months (Table 1). Thus, it is still 
questionable whether the administration of TKIs for more 
than 24 months could be burdened by toxicity and could 
facilitate the onset of biological resistance to treatment. 
In conclusion, the ADJUVANT trial is the first head-to-
head study showing a statistically significant DFS activity 
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with adjuvant gefitinib compared to standard chemotherapy; 
data about OS are awaited to support the clinical use of 
gefitinib in adjuvant EGFR-mutated NSCLC.
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